EU EMA Medicines Brief

Headline

EMA's CHMP recommends revoking EU marketing authorisation for Tavneos on data integrity grounds

Executive Summary

The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended revoking the EU marketing authorisation for Tavneos (avacopan), finding that the pivotal Advocate study was conducted in breach of good clinical practice principles. The European Commission will now issue the final legally binding decision, applicable across all EU Member States.

Bottom Line

The CHMP recommends revoking Tavneos' EU marketing authorisation on the basis that the pivotal study was conducted in breach of good clinical practice principles and its data can no longer demonstrate the medicine's effectiveness. The recommendation advises against new patient starts and advises switching existing patients to alternatives, with structured liver function monitoring for those stopping treatment. The European Commission issues the final legally binding decision applicable across all EU Member States; the CHMP opinion is not itself that decision.

Key Regulatory Signals

• Data Integrity Breach Drives Revocation Recommendation: The CHMP concluded that data from the Advocate study, the 331-patient trial supporting Tavneos' original authorisation, were incorrect and misleading and could no longer support a demonstration of effectiveness. Supportive post-marketing data and post-hoc analyses of the same study were not considered sufficient to fill the evidentiary gap.
• CHMP Recommends Against New Patient Starts and Advises Switching Existing Patients: The CHMP is recommending that no new patients should start treatment with Tavneos, and that existing patients should be switched to suitable alternatives. Cresthaven reading: prescribers and dispensers across EU Member States face a clinical transition question for any patient currently on Tavneos, pending the European Commission's final decision.
• Liver Monitoring Schedules Advised for Patients Stopping Treatment: The source states that liver function of patients treated with Tavneos should be closely monitored until treatment is permanently stopped, given the medicine's association with drug-induced liver injury and vanishing bile duct syndrome, including cases with fatal outcomes. For patients treated for fewer than three months, monitoring at least every two weeks until three months from treatment start is advised; for those treated longer than three months, monitoring every four weeks for up to six months, then as considered necessary, is advised. The source states Tavneos must be immediately discontinued if vanishing bile duct syndrome is suspected.
• Direct Healthcare Professional Communication Forthcoming: A direct healthcare professional communication (DHPC) containing the CHMP's recommendations and monitoring guidance is to be sent to prescribers, dispensers, and administrators of Tavneos in due course, with publication on EMA's DHPC page to follow. The European Commission's final decision, once issued, will be legally binding in all EU Member States.

Regulatory Delta

No direct precedent exists for a CHMP revocation recommendation grounded specifically in good clinical practice data integrity findings on a pivotal study, rather than a post-authorisation safety signal alone. This is a meaningful procedural distinction.

The CHMP's conclusion that post-marketing and post-hoc data are insufficient to rescue the authorisation marks a structural departure from cases where real-world evidence has bridged an evidentiary gap. Sponsors should not assume that supplementary data will compensate for foundational trial conduct failures.

Separately, the Pharmacovigilance Risk Assessment Committee (PRAC) issued parallel recommendations on reinforced liver function monitoring, reflecting coordinated review across EMA's safety committee structure.

Materiality Classification

MEDIUM — A CHMP recommendation for revocation, not a final European Commission decision; the recommendation advises clinical transition steps for a named medicine across the EU patient population and triggers a forthcoming DHPC to prescribers and dispensers sector-wide.

Intelligence Outlook

Monitor the European Commission for the final legally binding decision on this revocation recommendation, and monitor EMA's DHPC page for publication of the direct healthcare professional communication.